Investors stump up €15.5m more for Affimed
This article was originally published in Scrip
The German antibody therapeutics company Affimed has closed a €15.5 million series D financing round led by existing investors Aeris Capital, BioMedInvest, LSP Life Science Partners, Novo Nordisk and Orbimed, bringing up to €68.5 million the total amount of venture capital it has raised since it was founded in 2000. The money will be used for the clinical development of its two lead candidates, AFM11 and AFM13, which are currently in preclinical and Phase I trials, respectively.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.